A Strategic Assessment of the Cell and Gene Therapy Market
Genezen sought to assess how biopharmaceutical companies and payor organizations, predominately in North America, Europe, and Asia, are navigating reimbursement negotiations for commercial cell and gene therapies through a targeted survey. The survey engaged those in clinical development leadership and executive management, shedding light on the impact reimbursement strategies have on developmental pipelines and investor attitudes. The resulting report informed Genezen’s teams to engage with innovators more effectively and tailor its technology stack to changing demands.
